Osthole shows the potential to overcome P-glycoprotein-mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway

Oncology Reports

Volumn 35, Issue 6, 2016, Pages 3659-3668

  Wang, Hong ^a   Jia, Xiu Hong ^a   Chen, Jie Ru ^a   Wang, Jian Yong ^a   Li, You Jie ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chronic myeloid leukemia; Multidrug resistance; P glycoprotein; Phosphoinositide 3 kinase

Indexed keywords

DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OSTHOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHODAMINE 123; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; COUMARIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG POTENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; K562 CELL LINE; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; K-562 CELL LINE; LEUKEMIA, MYELOID; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COUMARINS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; P-GLYCOPROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RHODAMINE 123; SIGNAL TRANSDUCTION;

EID: 84964862002     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4730     Document Type: Article

References (42)

1. Mathisen MS, Kantarjian HM, Cortes J and Jabbour E: Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica 96: 347-349, 2011.
2. Cao R, Wang Y and Huang N: Discovery of 2- Acylaminothiophene-3- carboxamides as multitarget inhibitors for BCR-ABL kinase and microtubules. J Chem Inf Model 55: 2435-2442, 2015.
3. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, et al: Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention- To- Treat analysis. J Clin Oncol 26: 3358-3363, 2008.
4. Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, et al: Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68: 9809-9816, 2008.
5. Wei YL, Xu L, Liang Y, Xu XH and Zhao XY: Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. Acta Pharmacol Sin 30: 451-457, 2009.
6. Corrêa S, Binato R, Du Rocher B, Castelo-Branco MT, Pizzatti L and Abdelhay E: Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer 12: 303, 2012.
7. Souza PS, Vasconcelos FC, De Souza Reis FR, Nestal De Moraes G and Maia RC: P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int J Oncol 39: 925-933, 2011.
8. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: From genomics to mechanism. Oncogene 22: 7468-7485, 2003.
9. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M and Mahon FX: Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112: 2024-2027, 2008.
10. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562, 2009.
11. Cao H, Dronadula N and Rao GN: Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells. Am J Physiol Cell Physiol 290: C172-C182, 2006.
12. Hales EC, Taub JW and Matherly LH: New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal 26: 149-161, 2014.
13. Kumar N, Afeyan R, Sheppard S, Harms B and Lauffenburger DA: Quantitative analysis of Akt phosphorylation and activity in response to EGF and insulin treatment. Biochem Biophys Res Commun 354: 14-20, 2007.
14. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD and Kwiatkowski DJ: PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 117: 730-738, 2007.
15. García MG, Alaniz LD, Cordo Russo RI, Alvarez E and Hajos SE: PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk Res 33: 288-296, 2009.
16. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA and Martelli AM: The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T- Acute leukemia cells by a JNK-dependent mechanism. Leukemia 22: 1106-1116, 2008.
17. Xie X, Tang B, Zhou J, Gao Q and Zhang P: Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep 30: 773-782, 2013.
18. Cheng L, Luo S, Jin C, Ma H, Zhou H and Jia L: FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis 4: E923, 2013.
19. Mao Z, Zhou J, Luan J, Sheng W, Shen X and Dong X: Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells. Biomed Pharmacother 68: 179-183, 2014.
20. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA, et al: Multidrug resistance- Associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21: 427-438, 2007.
21. Yang HY, Hsu YF, Chiu PT, Ho SJ, Wang CH, Chi CC, Huang YH, Lee CF, Li YS, Ou G, et al: Anti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: Targeting vascular endothelial growth factor receptor signaling and angiogenesis. PLoS One 8: E81592, 2013.
22. Hu Y, Wen Q, Liang W, Kang T, Ren L, Zhang N, Zhao D, Sun D and Yang J: Osthole reverses beta- Amyloid peptide cytotoxicity on neural cells by enhancing cyclic AMP response element-binding protein phosphorylation. Biol Pharm Bull 36: 1950-1958, 2013.
23. Chou SY, Hsu CS, Wang KT, Wang MC and Wang CC: Antitumor effects of osthol from Cnidium monnieri: An in vitro and in vivo study. Phytother Res 21: 226-230, 2007.
24. Jarzab A, Grabarska A, Kiełbus M, Jeleniewicz W, Dmoszynska-Graniczka M, Skalicka-Wozniak K, Sieniawska E, Polberg K and Stepulak A: Osthole induces apoptosis, suppresses cell-cycle progression and proliferation of cancer cells. Anticancer Res 34: 6473-6480, 2014.
25. Liu LY, Huang WJ, Ho FM, Lin RJ, Lin SY, Suk FM and Liang YC: N-Hydroxycinnamide derivatives of osthole inhibit cell migration and invasion by suppressing Smad2 and Akt pathways in human colorectal adenocarcinoma cells. Chem Biol Interact 217: 1-8, 2014.
26. Tsai CF, Yeh WL, Chen JH, Lin C, Huang SS and Lu DY: Osthole suppresses the migratory ability of human glioblastoma multiforme cells via inhibition of focal adhesion kinase-mediated matrix metalloproteinase-13 expression. Int J Mol Sci 15: 3889-3903, 2014.
27. Xu XM, Zhang Y, Qu D, Feng XW, Chen Y and Zhao L: Osthole suppresses migration and invasion of A549 human lung cancer cells through inhibition of matrix metalloproteinase-2 and matrix metallopeptidase-9 in vitro. Mol Med Rep 6: 1018-1022, 2012.
28. Ye Y, Han X, Guo B, Sun Z and Liu S: Combination treatment with platycodin D and osthole inhibits cell proliferation and invasion in mammary carcinoma cell lines. Environ Toxicol Pharmacol 36: 115-124, 2013.
29. Zhang L, Jiang G, Yao F, He Y, Liang G, Zhang Y, Hu B, Wu Y, Li Y and Liu H: Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. PLoS One 7: E37865, 2012.
30. Yang HY, Zhao L, Yang Z, Zhao Q, Qiang L, Ha J, Li ZY, You QD and Guo QL: Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-κB signaling pathway. Mol Carcinog 51: 185-195, 2012.
31. Xu X, Zhang Y, Li W, Miao H, Zhang H, Zhou Y, Li Z, You Q, Zhao L and Guo Q: Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochem Pharmacol 92: 220-234, 2014.
32. Barancík M, Bohácová V, Sedlák J, Sulová Z and Breier A: LY294, 002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 29: 426-434, 2006.
33. Lau MT and Leung PC: The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett 326: 191-198, 2012.
34. Li X, Sun B, Zhu CJ, Yuan HQ, Shi YQ, Gao J, Li SJ and Lou HX: Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Toxicol In Vitro 23: 29-36, 2009.
35. Zhu H, Liu Z, Tang L, Liu J, Zhou M, Xie F, Wang Z, Wang Y, Shen S, Hu L, et al: Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells. Eur J Pharmacol 696: 43-53, 2012.
36. Kim TE, Lee H, Lim KS, Lee S, Yoon SH, Park KM, Han H, Shin SG, Jang IJ, Yu KS, et al: Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol 78: 556-564, 2014.
37. Palmeira A, Sousa E, Vasconcelos MH and Pinto MM: Three decades of P-gp inhibitors: Skimming through several generations and scaffolds. Curr Med Chem 19: 1946-2025, 2012.
38. Sprachman MM, Laughney AM, Kohler RH and Weissleder R: In vivo imaging of multidrug resistance using a third generation MDR1 inhibitor. Bioconjug Chem 25: 1137-1142, 2014.
39. Zhang X, Dong W, Zhou H, Li H, Wang N, Miao X and Jia L: α-2, 8-Sialyltransferase is involved in the development of multidrug resistance via PI3K/Akt pathway in human chronic myeloid leukemia. IUBMB Life 67: 77-87, 2015.
40. Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, Miyamura T, Yamashita N, Oda M and Morishima T: Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 59: 83-89, 2012.
41. Han Z, Hong L, Han Y, Wu K, Han S, Shen H, Li C, Yao L, Qiao T and Fan D: Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 26: 261-268, 2007.
42. Lin X, Zhang X, Wang Q, Li J, Zhang P, Zhao M and Li X: Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line. Neoplasma 59: 248-256, 2012.